Table 1.
Subject demographics and baseline characteristics
| Characteristic | Lyophilized palivizumab (n = 202) | Liquid palivizumab (n = 211) | Total (n = 413) |
|---|---|---|---|
| Age (months) | |||
| Mean (SD) | 4.0 (4.2) | 4.6 (4.5) | 4.3 (4.3) |
| Median | 2.9 | 3.4 | 3.2 |
| Range | 0.2–22.9 | 0.2–23.6 | 0.2–23.6 |
| Gestational age (weeks) | |||
| Mean (SD) | 32.7 (2.5) | 32.4 (2.7) | 32.5 (2.6) |
| Median | 34.0 | 33.0 | 34.0 |
| Range | 24–36 | 24–38 | 24–38 |
| Gender, n (%) | |||
| Male | 103 (51.0) | 107 (50.7) | 210 (50.8) |
| Race, n (%) | |||
| White/non-Hispanic | 149 (73.8) | 151 (71.6) | 300 (72.6) |
| Black | 24 (11.9) | 25 (11.8) | 49 (11.9) |
| Hispanic | 14 (6.9) | 22 (10.4) | 36 (8.7) |
| Asian | 3 (1.5) | 1 (0.5) | 4 (1.0) |
| Other | 12 (5.9) | 12 (5.7) | 24 (5.8) |
| Weight at day 0 (kg) | |||
| Mean (SD) | 5.1 (2.3) | 5.3 (2.3) | 5.2 (2.3) |
| Median | 4.74 | 5.20 | 5.00 |
| Range | 1.8–13.8 | 1.8–14.5 | 1.8–14.5 |
| CLD of prematurity, n (%) | |||
| Yes | 26 (12.9) | 35 (16.6) | 61 (14.8) |
CLD Chronic lung disease, SD standard deviation